Adults with Cystic Fibrosis (CF) & Exercise Intolerance Request More Information Trial Objective This exercise study is investigating how an already FDA approved drug for treatment of pulmonary vascular disease, sildenafil (Revatio ®), impacts exercise tolerance and capacity in people with cystic fibrosis (CF). Understanding and developing exercise tolerance is important for people with CF. Participants will be randomized to either the study drug group or the placebo group and complete exercise testing. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate Individuals with moderate to severe CF lung disease. Age: 18+ Gender: Any Gender Estimated Time Commitment 16 weeks, five in-person visits, three phone contacts × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Rachel Janney 303.270.2321 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Jewish Health and Dr. Taylor-Cousar, with Cystic Fibrosis Foundation via Augusta University Principal Investigators Jennifer Taylor-Cousar, MD, MSCS + × Jennifer Taylor-Cousar, MD, MSCS Medical Director, Clinical Research Services Co-Director, Adult Cystic Fibrosis Program Director, Cystic Fibrosis Therapeutics Development Center Adult Program Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine Division of Pediatric Pulmonary Medicine Department of Pediatrics President, Medical Staff View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective This exercise study is investigating how an already FDA approved drug for treatment of pulmonary vascular disease, sildenafil (Revatio ®), impacts exercise tolerance and capacity in people with cystic fibrosis (CF). Understanding and developing exercise tolerance is important for people with CF. Participants will be randomized to either the study drug group or the placebo group and complete exercise testing.